Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05124405 Active, not recruiting - Cancer Clinical Trials

Monitoring Your Exercise-related Metrics Over Time Via Wearable Electronic Devices

Start date: May 24, 2018
Phase: N/A
Study type: Interventional

To test the use of a continuous activity and heart rate tracker (Fitbit) and continuous glucose monitor (CGM) in monitoring daily exercise-related activities.

NCT ID: NCT05115422 Active, not recruiting - Cancer Clinical Trials

Feasibility and Acceptability of a Virtual 'Coping With Brain Fog' Intervention for Young Adults With Cancer

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

Cancer-related cognitive problems, also known as "brain fog", have a significant impact on patients with cancer and cancer survivors. Previous studies indicate that cancer and cancer treatments can negatively affect memory, attention and thinking abilities. Adolescents and young adults (AYAs) are individuals with a cancer diagnosis, who are currently between 18 to 40 years old. These individuals are especially vulnerable to brain fog symptoms due to the effect these symptoms have on their education, employment, health behaviors, mental health, and social relationships. There is a clear need for programming directed at brain fog symptoms among AYAs with cancer diagnoses. The 'Coping with Brain Fog' program, developed by Maximum Capacity Inc., is an eight-week group program that has been designed to educate patients about their brain fog symptoms and develop strategies to manage these symptoms. In this study the investigators will aim to determine the feasibility of adapting the 'Coping with Brain Fog' program to the virtual setting for AYAs with cancer during the COVID-19 pandemic. The investigators will also aim to explore the efficacy of the program on cognitive functioning and symptoms of anxiety, depression and fatigue. This study is an important step towards finding ways to treat brain fog symptoms in cancer patients, and could help guide future studies and programs.

NCT ID: NCT05080361 Active, not recruiting - Cancer Clinical Trials

Rechallenge of BRAF +/- MEK Inhibitors Following an Adverse Event in Patients With Cancer

Start date: January 1, 2011
Study type: Observational

Very little data are published on the safety of a rechallenge with a BRAF inhibitor or combination of BRAF and MEK inhibitor (BRAFi and MEKi) after an adverse event (AE). This study aimed at identifying the recurrence rate of the same AE after a BRAFi +/- MEKi rechallenge in patients with cancer and the factors associated to the recurrence.

NCT ID: NCT04967209 Active, not recruiting - Breast Cancer Clinical Trials

Investigation of a Digital Healthy Habits Program for Individuals With Breast Cancer

Start date: July 5, 2021
Study type: Observational

This mixed methods study will involve obtaining user feedback on the first 4 weeks of the Healthy Habits for Cancer (HCC) Program. Short pre and post surveys and in-depth qualitative interviews will be conducted exploring their views on the app (features they liked and didn't like), the extent to which they believe the app would have to be further adapted, how they would feel about such an app being embedded in their cancer care and when in their care pathway they would like to be offered it.

NCT ID: NCT04942756 Active, not recruiting - Cancer Clinical Trials

GLYPALCARE STUDY - Multicenter, Randomized Study for Evaluating Continuous Glucose Monitoring (CGM) by Using FreeStyle Libre 2 (FSL2) for Preventing Hyperglycemia/Hypoglycemia Crisis in Advanced Oncological Patients.

Start date: June 30, 2021
Phase: N/A
Study type: Interventional

Cancer patients with known or newly diagnosed (i.e. iatrogenic) Diabetes Mellitus (DM) in Palliative/Supportive Care will be enrolled. Patients will be randomly assigned to one of two groups. Patients included in the first group will monitor glucose levels through Continuous Glucose Monitoring (CGM), using the FreeStyle Libre 2 (FSL2). The second group is represented by the usual standard way for blood glucose (BG) monitoring (lancing device for finger samples). An interim analysis is foreseen when the half of the expected events (hyperglycemic peaks) will be observed. In case the results of interim analysis show superiority of the CGM (FSL2) group patients of the second group will be switched.

NCT ID: NCT04936997 Active, not recruiting - Cancer Clinical Trials

Immune Response to the COVID-19 Vaccine

Start date: June 7, 2021
Phase: Early Phase 1
Study type: Interventional

Explore the effects on immune response to include a potential third vaccine for the cancer cohort.

NCT ID: NCT04778878 Active, not recruiting - Cancer Clinical Trials

Assessment of Chemotherapy-induced Peripheral Neurotoxicity Using a Point-of-care Nerve Conduction Study Device

Start date: October 1, 2019
Study type: Observational

The purpose of this study is to evaluate the feasibility of the Mediracer® NCS device in early detection of CIPN in patients receiving potentially neurotoxic substance (vincristine, oxaliplatin or docetaxel) as a part of their chemotherapy regimen.

NCT ID: NCT04750915 Active, not recruiting - Cancer Clinical Trials

NIH-AARP Diet and Health Secondary Research Study Based on OH95CN025 Data

Start date: February 9, 2021
Study type: Observational

Background: The NIH and the American Association of Retired Persons (AARP) conducted a Diet and Health Study. It studied the links between diet, cancer, and cause of death in a group of middle-aged people in the U.S. Researchers want to learn more about how diet and lifestyle can affect cancer and mortality. Objective: To clarify links between diet, lifestyle, cancer, death, and chronic diseases. Eligibility: AARP members ages 50 to 71 who took part in study #OH95CN025 and lived in California, Florida, Pennsylvania, New Jersey, North Carolina, Louisiana, Atlanta, or Detroit in 1995 1996. Design: This study will use existing data and samples. Participants will not be contacted. Participants personal data, like name, date of birth, and address, will be used. This data will be kept private. Their data and samples will get a unique ID. Data from other follow-up studies will be used. Cancer outcome data will be obtained from the 8 sample areas. Many participants have moved to Arizona, Nevada, and Texas. Data will be obtained from those states as well. Cause of death and date of death will be obtained from the National Death Index. Cheek swab samples were gathered from 2004 to 2005. They will be used to study the oral microbiome. The University of Washington (UW) will be added as a study site. UW will study air pollution. The process of linking with the Virtual Pooled Registry Cancer Linkage System will be explored. It uses one system. Right now, 11 state systems are used to get and link data. Paper records will be stored in locked file rooms. Electronic data will be stored on secure servers.

NCT ID: NCT04724005 Active, not recruiting - Cancer Clinical Trials

Project Affinity: Excess Cancer Blood Testing

Start date: April 15, 2021
Study type: Observational

Study investigating cancer blood samples on an iterative measurement systme

NCT ID: NCT04715438 Active, not recruiting - Cancer Clinical Trials

Vaccination Against COVID-19 in Cancer

Start date: January 8, 2021
Phase: N/A
Study type: Interventional

This study will collect information on immune response and adverse events after vaccination against coronavirus disease (COVID-19) in a vulnerable patient cohort. Understanding the ability or disability to mount a protective immune response after vaccination will help to counsel patients during the pandemic and support decisions on whom to vaccinate and to identify patients who require other measures to protect them from COVID-19.